Learn how and where to inject Zepbound and where to get additional help. Plus, get tips for injecting the drug at home and ...

Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Serkan Oray from UCB shares why the autoinjector pen format is booming, the importance of a patient-centric design, and how ...

The MedTech division grew 4.1%, driven by acquisitions, while Pharmaceuticals saw a 4.2% increase, despite challenges like Stelara's patent expiry. JNJ raised its full-year revenue guidance and ...

Joaquin Duato; Chairman of the Board, Chief Executive Officer; Johnson & Johnson John Reed; Executive Vice President - Innovative Medicine, Research and Development; Johnson & Johnson Joseph Wolk ...

Chicago, IL – April 16, 2025 – Today, Zacks Equity Research Equity are Dr. Reddy’s Laboratories RDY, Sandoz SDZNY and Teva Pharmaceuticals TEVA. Industry: Generic Drugs Link: https://www ...

That is despite a decline in sales after the patent expiry of Stelara, the company's blockbuster inflammatory condition treatment, this year. On an earnings call Tuesday, executives said that China, ...

[SINGAPORE] Olam Group will invest US$500 million equity into Olam Food Ingredients (ofi) within the next three months, while de-leveraging the remaining Olam group for progressive liquidation, as ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

Welcome to the Peruvian Nuevo Sol exchange rate & live currency converter page. The Peruvian Nuevo Sol (PEN) exchange rates represented on this page are live, updated every minute within the forex ...

Johnson & Johnson has three of its top-selling drugs in Medicare pricing negotiations – Stelara, Xarelto, and Imbruvica – but has said it does not expect a major hit to its finances next year.